Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
Larimar Announces the Dosing of the First Patient in Study for Nomlabofusp
Larimar to Present at the Leerink Partners Global Biopharma Conference
Larimar Announces Closing of Underwritten Public Offering of Common Stock
BALA CYNWYD, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (œLarimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
BALA CYNWYD, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (œLarimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
Larimar Therapeutics announced Monday that its Friedreich’s ataxia treatment increased median levels of a key protein called frataxin in a mid-stage study.
Completed full enrollment and dosing of the 50 mg cohort in Phase 2 Friedreich's ataxia (FA) dose exploration trial; based on blinded observations during the dosing period, there were no serious...
BALA CYNWYD, Pa., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...
BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (œLarimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare...